WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011140375) METHODS OF REDUCING SYMPTOMS IN SUBJECTS USING SINGLE DOSAGE FORMS WITH TAPERING RELEASE RATES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/140375    International Application No.:    PCT/US2011/035402
Publication Date: 10.11.2011 International Filing Date: 05.05.2011
IPC:
C07J 71/00 (2006.01)
Applicants: TEVA WOMEN'S HEALTH, INC. [US/US]; 400 Chestnut Ridge Road Woodcliff Lake, NJ 07677 (US).
DILIBERTI, Charles, E. [US/US]; (US) (For US Only).
MAHASHABDE, Anu [US/US]; (US) (For US Only)
Inventors: DILIBERTI, Charles, E.; (US).
MAHASHABDE, Anu; (US)
Agent: WOODHOUSE, Scott, M.; Fanelli Haag PLLC 1909 K Street N.W. Suite 1120 Washington, DC 20006 (US)
Priority Data:
61/331,775 05.05.2010 US
Title (EN) METHODS OF REDUCING SYMPTOMS IN SUBJECTS USING SINGLE DOSAGE FORMS WITH TAPERING RELEASE RATES
(FR) PROCÉDÉS DE RÉDUCTION DES SYMPTÔMES CHEZ DES SUJETS À L'AIDE DE FORMES POSOLOGIQUES INDIVIDUELLES AYANT DES VITESSES DE LIBÉRATION DÉGRESSIVES
Abstract: front page image
(EN)The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.
(FR)La présente invention porte sur des procédés de réduction de symptômes associés à une réduction brutale d'un agent chimique endogène ou exogène chez des sujets, les procédés comprenant : (a) l'administration au sujet d'une forme posologique comprenant un agent actif, la vitesse de libération de l'agent actif provenant de la forme posologique individuelle diminuant tout au cours de l'administration ; et (b) le retrait de la forme posologique à partir des sujets après que la vitesse de libération de l'agent actif est à ou au-dessous d'un niveau de seuil de symptôme terminal.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)